Lilly extends study of highly anticipated cholesterol fighter

Eric Palmer

Eli says it will extend the massive Phase III trial for its highly drug candidate evacetrapib, a CETP inhibitor that works to lower LDL, or "bad," levels and raise HDL, or "good," levels, by 6 months.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS